Incyte (INCY) Tops Q2 EPS by 36c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Delta Air Lines (DAL) Raises Quarterly Dividend 14.7% to $0.2150; 1% Yield
- ICC sets July 24 vote on whether to remove chief prosecutor Karim Khan, WSJ reports
Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
August 4, 2020 7:00 AM EDTTotal product and royalty revenues of $593 million (+16% vs Q2 2019) for the quarter ended June 30, 2020; Jakafi® (ruxolitinib) revenues of $474 million in Q2 2020 (+16% vs Q2 2019) Monjuvi® (tafasitamab-cxix; collaboration with MorphoSys) approved by U.S. FDA; launch preparations already underway TabrectaTM (capmatinib; licensed to Novartis) approved by U.S. FDA and Japanese MHLW; Incyte eligible for milestones and royalties on global net sales Primary and both key secondary endpoints met in Phase 3 REACH3 trial of Jakafi in patients with steroid-refractory chronic graft-versus-host disease
Conference... More
